Iovance Biotherapeutics Inc

IOVA remains in a Stage 2 advancing regime with a clear momentum breakout and higher-highs/higher-lows structure, but price is extended well above rising 9/21 EMAs and in extreme overbought territory. Under the Momentum + EPS strategy, we defer execution and stalk for a shallow pullback into the EMA support zone for a better entry.

• ↑Q1 revenue $71M (+45% YoY); 2026 forecast $350–370M (+36%).
• ↑Gross margin ~41%; cash $319M funds operations into 2028.
• ↓Negative earnings yield and -123.9% profit margin highlight unprofitable operations.